Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • 1700 percent on items...

    1700 percent on items charged by Fortis Memorial Research Institute, says NPPA

    Written by Ruby Khatun Khatun Published On 2017-12-16T16:47:13+05:30  |  Updated On 13 Aug 2021 3:45 PM IST

    Gurugram: Fortis hospital at Gurugram charged as high as 1700 percent cent margin on consumables and medicines used for the treatment of a dengue patient who subsequently died of the illness, the National Pharmaceutical Pricing Authority (NPPA) said.


    Fortis Memorial Research Institute, Gurgaon, charged a margin of up to 1,737 percent on procurement price on a three-way stop cock, the regulator said.


    The procurement price of the consumable per unit stood at Rs 5.77 while the hospital charged Rs 106 per unit for the product, it added.


    The consumables listed by the NPPA included items such as syringes, gloves, and towels among others.


    Last month, the NPPA had asked Fortis Healthcare to provide copies of bills in relation to allegations that its Gurgaon-based hospital overcharged the family of a seven-year-old girl, who died of dengue.


    Read also: Hospital Overcharging case: Fortis now gets NPPA notice seeking bill copies

    Regarding the non-scheduled formulations, NPPA said the hospital charged the family a margin as high as 914 percent.


    Elaborating, the NPPA said the hospital charged Rs 287.50 for Dotamin 200 mg whose procurement price per unit stood at Rs 28.35, a margin of 914 percent.


    Fortis also charged Rs 3,112.50 for Merocrit 1 GM thus charging a margin of 670 percent. The hospital had procured the formulation at Rs 404.32 per unit, the regulator said.


    Regarding the scheduled formulations which are under the ambit of price control, the NPPA said the hospital charged up to 343 percent from the family of Adya.


    The per unit procurement price of Tranemic by the hospital stood at Rs 15.75 while it was billed at Rs 69.77 per unit to the family.


    The regulator gave a list of 39 scheduled formulations, 41 non-scheduled formulations and 96 consumables that were used for the treatment of Adya.


    "NPPA shall be taking necessary follow up action as per existing law and with in its jurisdiction," the regulator said.


    The drug authority's action came after the Union Health Ministry asked all states to issue strict warnings and take action against hospitals, including private ones, which indulge in malpractices such as overcharging and do not follow standard treatment protocols.


    Below is the attachment for the same.

    1700 percent profitDotaminFMRIFortisFortis HealthcareFortis HospitalFortis Memorial Research InstituteGurugram hospitalNational Pharmaceutical Pricing Authoritynon-scheduled formulationsNPPAScheduled formulationsUnion Health Ministry
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok